Arcera Life Sciences releases inaugural Sustainability Report
The 2024 report outlines Arcera’s current ESG initiatives and long-term ambitions, including a firm commitment to achieving full carbon neutrality...
Acino Publishes Second Annual Sustainability Report
Report underscores Acino’s continued commitment to Environmental, Social, and Governance goals, including a firm commitment to reaching full carbon neutrality...
Your partner for innovative medicines in emerging markets
We have expanded our portfolio with several novel products, marking a significant step forward in our effort to help more...
Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa
Cardiovascular diseases get Acino employees to open their hearts
This year’s World Heart Day (WHD) generated some truly heartfelt stories across all our global regions.
Acino Recognizes World Heart Day 2023
Acino, recognizes the significance of cardiovascular health and is dedicated to advancing heart care through innovative solutions and patient education....
Acino releases company’s first ever Sustainability Report
Report reflects Acino’s commitment to Environmental, Social, and Governance sustainability including goal of reaching carbon neutrality by 2050.
Acino signs exclusive license agreement with Bioprojet for treatment of narcolepsy and obstructive sleeping apnoea (OSA)
This agreement strengthens Acino’s position in the Central Nervous System (CNS) therapeutic area and paves the way for greater patient...
Acino and Batterjee Pharma sign partnership agreement to support Saudi Arabia’s Health Sector Transformation Programmme
The agreement between Acino and Batterjee covers the licensing, manufacturing, and supply of select Acino products across the Kingdom, based...